Economic Evaluation of Chimeric Antigen Receptor T-Cell Therapy by Site of Care Among Patients With Relapsed or Refractory Large B-Cell Lymphoma

IMPORTANCE: Chimeric antigen receptor (CAR) T-cell therapies are currently administered at a limited number of cancer centers and are primarily delivered in an inpatient setting. However, variations in total costs associated with these therapies remain unknown. OBJECTIVE: To estimate the economic di...

Descripción completa

Detalles Bibliográficos
Autores principales: Lyman, Gary H., Nguyen, Andy, Snyder, Sophie, Gitlin, Matthew, Chung, Karen C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136832/
https://www.ncbi.nlm.nih.gov/pubmed/32250433
http://dx.doi.org/10.1001/jamanetworkopen.2020.2072

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136832/
https://www.ncbi.nlm.nih.gov/pubmed/32250433
http://dx.doi.org/10.1001/jamanetworkopen.2020.2072

Ejemplares similares